Division of Medicinal Chemistry Abstracts-235th ACS National ...
Division of Medicinal Chemistry Abstracts-235th ACS National ...
Division of Medicinal Chemistry Abstracts-235th ACS National ...
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
established presence <strong>of</strong> NK-2 in the CNS suggests potential anxiolytic/antidepressant properties<br />
for NK-2 receptor antagonists. Therefore, the objective <strong>of</strong> this early phase research program<br />
was to develop a selective, potent and orally - active Neurokinin 2- receptor antagonist for the<br />
treatment <strong>of</strong> depression. The design, synthesis and evaluation <strong>of</strong> potent NK-2 receptor<br />
antagonists for the treatment <strong>of</strong> depression are described. Substituted piperidinyl 3,4-<br />
dihydroisoquinoline amides 1 were formally derived by a combination <strong>of</strong> classic SAR and<br />
solution phase library synthesis. Some members <strong>of</strong> this chemical series showed significant<br />
selectivity and binding affinity for the cloned human NK-2 receptor.<br />
MEDI 41<br />
Novel 5-HT2A/D2/Sigma receptor ligands: Psychiatric disorder treatment agents<br />
Yong-Gil Kim, Joon Heo, Seon-Min Dong, Yun-Hee Kim, and Byong-Sung Kwak, Drug<br />
Development Center, SK Holdings, 140-1, Wonchon-dong, Yuseong-gu, Daejeon 305-712,<br />
South Korea, Fax: 82-42-866-7702, yonggil.kim@sk.com, joon.heo@sk.com<br />
Agents potently acting on the sigma receptors may be useful in the therapy <strong>of</strong> CNS diseases.<br />
Also, creating a specific drug for sigma receptor interaction and finding the novel<br />
pharmacological effect are important for developing new types <strong>of</strong> drugs. In our research strategy<br />
for new CNS drugs, we designed a novel ligand for sigma receptors and 5-HT2A/D2 receptors,<br />
conventional mechanism <strong>of</strong> atypical antipsychotics, which has potent affinity for triple<br />
mechanism. Potential applications <strong>of</strong> triple mechanism ligands are the treatment <strong>of</strong> depression,<br />
psychosis, and so on. Through our research strategy, we discovered that members <strong>of</strong> this class<br />
compounds demonstrate to be effective for schizophrenia and depression. This poster will<br />
highlight the SAR and biological data <strong>of</strong> these compounds.<br />
MEDI 42<br />
Synthesis and structure-activity relationship <strong>of</strong> a series <strong>of</strong> alpha-azole substituted phenyl<br />
alkyl amines as 5-HT2A/D2 receptor ligands: Potential psychosis treatment agents